Article Figures & Data
Tables
- Table 1.
Current active phase II and III trials in NMIUC
Agent(s) Setting Triala Correlates DTA-H19/PEI Phase IIb, second line NCT00595088 Sunitinib Phase II, second line NCT01118351 CTCs, Tregs, angiogenic markers MCC Phase II/III NCT00406068 BCG ± gefitinib Phase III NCT00352079 Intravesicular nab-paclitaxel Phase I/II NCT00583349 Abbreviations: CTC, circulating tumor cell; Treg, regulatory T cell.
-
↵aClinicalTrials.gov registry number.
-
- Table 2.
Current active phase II trials in potentially resectable Urothelial carcinoma
Agent(s) Setting Triala Correlates Gem/carbo/paclitaxel Phase II, pot resect NCT00136175 P53, RB, p21 Gem/carbo/nab-pacli Phase II, neoadj NCT00585689 Sunitinib Phase II, neoadj NCT00526656 VEGFR-1, -2, PDGF-R, Treg Gem/cis/bev (neoadj) and pacli/bev (adj) Phase II, periop NCT00268450 pT0 cystoscopy, surgery MVAC + bev Phase II, neoadj NCT00506155 Assess angiogenesis and downstream pathways, including 2-color TUNEL, phospho-receptor, and microvessel density Erlotinib Phase II, neoadj NCT00749892 Sunitinib Phase II, adj in patients treated with neoadj NCT01042795 Dasatinib Phase II neoadj NCT00706641 Gem/cisplatin/sunitinib Phase II, neoadj NCT00847015 Abbreviations: adj, adjuvant; bev, bevacizumab; carbo, carboplatin; gem, gemcitabine; nab-pacli, nab-paclitaxel; neoadj, neoadjuvant; PDGF, platelet-derived growth factor; pot resect, potentially resectable.
-
↵aClinicalTrials.gov registry number.
-
- Table 3.
Current active phase II trials in metastatic Urothelial carcinoma
Agent(s) Setting Triala Gem/carbo/sorafinib Phase II, chemonaïve NCT00461851 Gem/sdcis/sorafinib Phase II, chemonaïve NCT00714948 Sunitinib Phase II, platinum ineligible NCT01118039 Sunitinib Phase II, platinum ineligible NCT00578526 Tesetaxel Phase II, second line NCT01215877 Gem/cis + sunitinib Phase II, first line NCT01089088 Eribulin Phase Ib/II NCT01126749 Everolimus ± paclitaxel Phase II, first line NCT01215136 Gem/cis ± cetuximab Randomized phase II NCT00645593 Gem/cisplat/eribulin Phase Ib/II, chemonaïve NCT01126749 Ixabepilone Phase II, second line NCT00021099 Kinesin spindle protein inhibitor Phase II, second line NCT00661609 Pralatrexate Phase II platinum and/or MTX R NCT00722553 Tipifarnib Phase II, chemonaïve NCT00006376 Larotaxel/cis vs. gem/cis Phase III, chemonaïve NCT00625664 Nab-paclitaxel/gem/carbo Phase II, chemonaïve NCT00995488 Omidepsin Phase II, second line NCT00087295 Lonafarnib/gem Phase II, second line NCT00006351 Gem/cis ± bev Phase III NCT00942331 Pazop/vinflunine Phase I/II, platinum R NCT01265940 Pazop Phase II, second line NCT00471536 Pazop Phase II, second line NCT01031875 Paclitaxel/pazop Phase II, second line NCT01108055 Dovitinib Phase II, second line NCT00790426 Volasertib Phase II, second line NCT01023958 Gem/cis ± vandetanib Randomized phase II, first line NCT01191892 Docetaxel ± IMC-1121b or -18F1 Randomized phase II NCT01282463 Abbreviations: bev, bevacizumab; carbo, carboplatin; gem, gemcitabine; MTX, methotrexate; R, resistant; sdcis, split dose cisplatin.
-
↵aClinicalTrials.gov registry number.
-
June 2012
Volume 11, Issue 6
Volume 11, Issue 6
New Directions for Biologic Targets in Urothelial Carcinoma
Jump to section
Advertisement